Connect with us

Technology

Selvita reports Q1 2026 results and launches strategic options review

Published

on

KRAKÓW, Poland, May 21, 2026 /PRNewswire/ — Selvita S.A. (WSE: SLV), one of the leading Drug Discovery and Development organizations in Europe, has published its financial results for Q1 2026 and latest backlog. The Company has decided to launch a strategic options review for the Group’s further development and to maximize long-term shareholder value.

The Group’s operating revenues in Q1 amounted to EUR 19.1 million, at the upper end of the preliminary estimated results range of EUR 18.4-19.3 million. The EBITDA margin(1) reached 14%, compared to the estimated range of 13-16%. As a result of the cost-saving program implemented in H2 2025, operating costs in Q1 2026 were reduced by approximately EUR 1.5 million.Drug Development segment: Commercial revenues increased by 6% y/y in Q1 2026 to EUR 6.2 million, representing 35% of the Group’s commercial revenues. Segment EBITDA amounted to EUR 1.7 million, up 2% y/y(1). Segment backlog increased 15% y/y supporting the Group’s expectation of continued future growth driven by strategic alignment to fast-growing modalities.Drug Discovery segment: Commercial revenues in Q1 2026 amounted to EUR 11.6 million, compared to EUR 15.6 million in the prior year. Segment EBITDA(1) amounted to EUR 1.0 million, compared to EUR 1.9 million in Q1 2025.  This was primarily due to the continuing challenging market for outsourced European drug discovery services companies and some project delays.The full-year 2026 backlog as of May 18, 2026 stands at EUR 58.1 million(2) compared to EUR 58.9 million last year.A webcast to discuss Selvita’s Q1 results and outlook for 2026 will be held on May 21 at 11:00 CET. The event will be available at live.selvita.comSelvita announced the launch of a strategic review to assess options to support the Group’s further development and maximize shareholder value.

Boguslaw Sieczkowski, Co-Founder, significant shareholder and Chief Executive Officer of Selvita said:

“We are observing a progressive recovery in the biotechnology sector, particularly in the United States. However, the market remains volatile, as reflected, amongst other factors, in our Q1 results. We are focusing our efforts on ensuring that the subsequent periods show clear improvement, reflecting the acceleration of growth in Drug Development and a stabilized performance in Drug Discovery. Our profitability is supported by the cost-saving program implemented in the second half of 2025.

“The Drug Development segment has grown by 20-25% in recent years and is now a key growth driver for the Group, already accounting for more than one-third of commercial revenues. We see potential for its further development and have identified specific pathways by which we can accelerate growth in this segment.

“The Drug Discovery segment continues its transformation, driven by ongoing structural changes in the outsourced European drug discovery services market. Last year, we optimized the segment’s resources. We are currently focusing our efforts on more complex, high-margin services and increasing automation.”

Dariusz Kurdas, Management Board Member and Chief Financial Officer of Selvita, said:

“With EUR 19.1 million in operating revenues and a 14% EBITDA margin, we came in the middle of the range of the Q1 preliminary estimates published earlier. In the Drug Discovery segment we observed some project delays. These projects are still expected in the remaining quarters of the year, supporting improved financial performance compared to Q1. This year, we expect an improvement in profitability thanks to the approximately EUR 6.4 million in savings under the optimization program.”

STRATEGIC OPTIONS REVIEW

Selvita has continued to observe contrasting market dynamics across Drug Discovery and Drug Development.

In Drug Discovery, the European outsourced services market has remained challenging. However, the Group sees encouraging signs in the biotechnology funding environment and preliminary signs of increased levels of new pipeline opportunities which will support improved performance for the remainder of 2026 compared to Q1. Over the medium term, the Group expects continued headwinds in certain areas of small molecule Drug Discovery, whilst demand for high value-add and integrated services, especially for advanced modalities, is expected to continue to grow.

In Drug Development, the Group expects to see continued momentum in demand for services, notably in fast-growing advanced modalities.

In light of this market backdrop, Selvita has commenced a broad strategic review to assess options which would support the Group in achieving larger scale and maximizing long-term shareholder value.

The Group is considering, and is open to, a variety of strategic options, which may include a take private transaction, or an acceleration of Selvita’s M&A and organic growth initiative capital deployment strategy. This includes scenarios where additional financing would be considered solely to support such value-accretive opportunities and incremental growth initiatives.

Selvita has not set a timetable for the review, nor has it made any decisions at this stage regarding the selection of or preference for any option. Updates on the conclusion of the strategic review will be publicly communicated by Selvita as and when appropriate, and in accordance with applicable regulations.

The strategic options review will be conducted with a strong focus on uninterrupted client service, operational stability, and continued excellence in project delivery.

To facilitate the strategic review, Selvita has engaged Rothschild & Co as financial adviser.

Boguslaw Sieczkowski said:

“It is our belief that the Drug Discovery and Drug Development markets are evolving to favour players of larger scale with broad geographic and service offering capabilities across modalities. We do not believe the Group’s current valuation reflects its growth trajectory in Drug Development and unique capabilities and market positioning in Drug Discovery. We, therefore, think that now is an appropriate time to assess our potential strategic options. The underlying premise of the process is to improve the prospects of each of the Group’s segments and deliver shareholder value.”

Q1 2026 FINANCIAL RESULTS

Operating revenues in Q1 2026 amounted to EUR 19.1 million, compared to EUR 21.8 million in the prior year. The negative impact of foreign exchange differences on revenues amounted to approximately EUR 0.2 million.

Group EBITDA in Q1 2026 amounted to EUR 2.7 million, compared to EUR 3.6 million in the prior year(1). The EBITDA margin reached 14%. Savings resulting from the implemented optimization program amounted to approximately EUR 1.5 million.

Commercial revenues in the Drug Discovery segment in Q1 2026 amounted to EUR 11.6 million, compared to EUR 15.6 million in the prior year. Segment EBITDA(1) amounted to EUR 1.0 million, compared to EUR 1.9 million in the prior year.

Commercial revenues in the Drug Development segment in Q1 2026 amounted to EUR 6.2 million, up 6% y/y, already accounting for 35% of total commercial revenues. Segment EBITDA reached EUR 1.7 million, up 2% y/y, corresponding to a margin of 27%(1).

BACKLOG FOR 2026(2)

The Group’s backlog for 2026 amounts to EUR 58.1 million compared to EUR 58.9 million in the same period last year.

The backlog in the Drug Discovery segment stands at EUR 35.3 million (down 13% y/y), while in the Drug Development segment it amounts to EUR 19.4 million (up 15% y/y).

DRUG DISCOVERY TECHNOLOGIES DEVELOPMENT PROGRAM FOR 2026-2029

In recent quarters, Selvita secured four non-dilutive grants with a combined subsidy value of EUR 26.4 million. Nearly half of this amount – EUR 12.0 million – will be invested in the development of advanced services in 2026-2029. Together, these projects represent the most intensive technology development program in the Group’s history, spanning most departments within the Drug Discovery segment and incorporating a significant AI component.

The remaining portion of the grant funding will support infrastructure development, including the acquisition of state-of-the-art equipment and, in 2028-2029, the expansion of Selvita’s own laboratory space in Kraków. The potential investment in new, specialized research facilities will be financed through a combination of grant funding (approx. 40%), bank debt (approx. 50%), and the Group’s own funds (approx. 10%). In March 2026, Selvita signed a loan agreement securing financing for the investment. The largest share of capital expenditures is planned for the final phase of the investment, scheduled for 2029.

     (1) Results exclude non-cash costs of the non-dilutive employee incentive program.
     (2) Backlog as of May 18, 2026 and May 19, 2025; includes the revenues already invoiced in the financial year and portfolio of orders for the financial year.

All % calculated from PLN. All values are calculated from PLN using an average exchange rate for the respective reporting period.

About Selvita (WSE: SLV; sWIG80)

Selvita is one of the leading Drug Discovery and Development organizations in Europe. The Company provides comprehensive solutions supporting clients and their programs across a broad range of therapeutic areas, with expertise in infectious diseases, inflammation, fibrosis, and oncology. Selvita offers a wide range of standalone and fully integrated drug discovery and development solutions. Its service portfolio spans the entire value chain, from early-stage drug discovery to preclinical development, for both small molecules and therapeutic antibodies.

The Selvita Group has been operating since 2007 and employs approximately 900 highly qualified specialists. More than 30% of Selvita’s scientists hold a PhD degree. The Group’s headquarters and main laboratories are located in Kraków, Poland, with additional research facilities in Poznań, Wrocław, and Zagreb, Croatia. The Company’s sales offices are located in major global biotech hubs, including the Boston and San Francisco Bay Areas in the United States, as well as Cambridge in the United Kingdom.

Selvita is listed on the Warsaw Stock Exchange (WSE: SLV) and is a component of the sWIG80 index.

For more information, please visit: www.selvita.com

 

View original content:https://www.prnewswire.com/news-releases/selvita-reports-q1-2026-results-and-launches-strategic-options-review-302778547.html

SOURCE Selvita S.A.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Behind the Scenes: Corra Group’s Media & Entertainment Background Checks Highlight the Importance of Human Expertise in an AI World

Published

on

By

LOS ANGELES, June 3, 2026 /PRNewswire/ — As film, television, streaming, commercial, and live event productions continue to accelerate in 2026, Corra Group is highlighting the growing importance of specialized background screening in an increasingly complex hiring environment shaped by AI-generated content, digital reputations, and fast-moving production timelines.

“Production companies today are operating in an environment where hiring often happens quickly, remotely, and across large networks of freelance talent and crew,” said Nick Gustavson, CEO of Corra Group. “It’s also becoming harder to separate fact from fiction online. Between AI-generated images, manipulated digital content, and misinformation, verification is more important than ever.”

With over two decades of experience supporting the media and entertainment industry, Corra Group provides customized media & entertainment background screening solutions designed specifically for entertainment production hiring — from major studio projects and network television to independent productions, commercial campaigns, live events, and unscripted programming.

“When questions come up, clients still want a real person they can call. Emerging technologies and AI are important, but so is having experienced people who understand the industry and know what to look for,” added Gustavson.

Corra Group’s Media & Entertainment screening solutions support a broad range of production-related roles, including:

Talent, cast members, contestants, and participants

On-camera experts, commentators, and contributors

Above-the-Line and Below-the-Line crew

Production drivers and transportation personnel, including talent transportation, grip and electric truck drivers, camera truck drivers, and production assistants operating company vehicles

Support personnel, including event staff, medics, therapists, wellbeing facilitators, and other production support roles

As streaming platforms, live productions, and commercial campaigns continue expanding, entertainment organizations face increased reputational, operational, and workplace safety considerations. Thorough background screening and social media checks can help productions identify potential concerns early, protecting the reputation of the production as well as the brands, networks, studios, and clients behind it.

“Anyone who has worked in production knows timelines can change overnight. Sometimes cast and crew members need to be onboarded right away,” added Gustavson. “We understand that urgency and have spent years helping production teams meet tight deadlines.”

Headquartered in the Los Angeles area, Corra Group has worked with organizations in media and entertainment for years, helping productions navigate high-volume hiring demands while maintaining a strong focus on compliance, turnaround time, and customer service. The company understands the operational realities of production hiring and works closely with clients to streamline onboarding, simplify billing processes, accommodate purchase order requirements, and provide responsive support throughout the screening process.

Corra Group’s Media & Entertainment offerings for checks include criminal history, social media, sex offender registries, derogatory public records, and MVRs. Clients also benefit from dedicated points of contact and personalized customer service, ensuring there is always an experienced team member available to help navigate production timelines and screening requirements. Industry professionals frequently cite Corra Group’s responsiveness, accuracy, personalized service, and ability to meet demanding production timelines.

About Corra Group

Corra Group is a full-service background screening and corporate research company providing employment screening, drug testing, due diligence, and investigative services to organizations across multiple industries, including media and entertainment, transportation, healthcare, financial services, and more. Based in the Los Angeles area, Corra Group is known for responsive customer service, customized screening solutions, and industry-specific expertise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/behind-the-scenes-corra-groups-media–entertainment-background-checks-highlight-the-importance-of-human-expertise-in-an-ai-world-302789811.html

SOURCE Corra Group

Continue Reading

Technology

Malwarebytes Launches Free Reverse Phone Check to Help Consumers Identify Potential Scam Numbers

Published

on

By

New standalone tool delivers fast, no-sign-in scam verification powered by Malwarebytes trusted threat intelligence

SANTA CLARA, Calif., June 3, 2026 /PRNewswire/ — Malwarebytes, a global leader in real-time cyber protection, today launched Malwarebytes Scam Number Check, a free, standalone web experience designed to help consumers quickly determine whether a phone number may be associated with scam activity. It answers the question, “is this phone number safe?” with a speedy reverse lookup tool. It also includes community context; users are alerted if other people have seen scam activity from the number, or they can report a number, providing additional information about the call or text type such as robocall, fraud and delivery.

Check if a phone number is safe: malwarebytes.com/scam-check/phone

Scammers stole more than $21 billion from Americans last year, according to the latest IC3 report. Malwarebytes Scam Guard data revealed phone-call assisted social engineering ranks among the top five types of scams illustrating that many start with what appears to be an innocent phone call or text from a legit phone number spoofed for malicious means. A simple check if the number is legit, or if others in their area have seen this scam provides valuable insights, empowering people to hang up and providing them with a platform to report the number. Powered by the Malwarebytes threat intelligence engine, the tool analyzes carrier data, contextual signals and known scam indicators from the millions of examples in the company’s database to surface relevant insights.

“Most people don’t have an IT department, a CISO or formal security training, but they’re still expected to navigate increasingly sophisticated scams,” said Michael Sherwood, VP of Product, Malwarebytes. “We need to give people simple, effective tools to fight back. The Scam Number Check offers a fast, trusted way to verify a phone number and make an informed decision. It also enables people to help others in their community by reporting scam and fraud calls, making everyone safer.”

Instead of revealing who a number belongs to, Malwarebytes focuses on what matters most: helping users quickly and confidently determine whether a number is safe and trustworthy – without compromising privacy. It also provides easy-to-follow recommendations on how to spot and avoid scams.

Key Features of Malwarebytes Scam Number Check

Free, no sign-in required reverse phone number lookupScam detection insights powered by Malwarebytes’ threat intelligence engine that scans and extracts bad phone numbers from malicious scam campaignsSocial proof through aggregated threat intelligence data

Malwarebytes Free Solutions

The Scam Number Check is part of Malwarebytes’ broader commitment to providing accessible, easy-to-use cybersecurity tools that help people stay safe online. It joins a growing suite of free resources designed to equip people with actionable security and privacy help such as:

Malwarebytes Virus Scanner and Malware Remover: Legendary tool for finding and cleaning up malware, spyware, trojans and viruses.Malwarebytes Browser Guard: Browser extension that blocks malware, scams, phishing and trackers for safer, cleaner, ad-free browsing.Malwarebytes Digital Footprint Scanner: Quick check to see if any sensitive information has been involved in a data breach, including accounts and passwords.Malwarebytes Personal Data Remover: Guidance on how to delete personal information from data broker lists, people search sites, and more.Malwarebytes AdwCleaner: Tool to find and remove unwanted programs and junkware to keep devices running fast.Malwarebytes Scam Guard: Scam detector combining the ease of an AI chat bot with the company’s deep threat intelligence expertise to check a suspicious text, link, DM or message alongside actionable guidance on what to do next.

To explore all free options, visit: www.malwarebytes.com/free-tools.

To read more about the latest threats and cyber protection strategies, visit the Malwarebytes blog, or follow us on Facebook, InstagramLinkedInTikTok, Reddit and X.

About Malwarebytes

Malwarebytes is reimagining security to safeguard devices, data and people, no matter their location, lifestyle or means. A global leader in online protection, its suite of award-winning cybersecurity, privacy and identity solutions empower millions of people worldwide to enjoy their digital lives, free from threats and scams. Built and beloved by experts, Malwarebytes pairs a world-class team of threat researchers with proprietary AI-powered processes to supercharge and refine detections, providing unmatched protection against both known and unknown threats. Living up to its legacy, Malwarebytes continues to offer free tools that have long served as a first line of defense against malware and scams with new options for identity protection and data removal.

Malwarebytes, powerful digital protection that’s always by your side.

Learn more: https://www.malwarebytes.com.

Malwarebytes Media Contact:
Ashley Stewart
Director of Public and Analyst Relations
press@malwarebytes.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/malwarebytes-launches-free-reverse-phone-check-to-help-consumers-identify-potential-scam-numbers-302778855.html

SOURCE Malwarebytes

Continue Reading

Technology

Contact Lenses Online (2026): EZContacts Recognized as Top Overall Retailer by Expert Consumers

Published

on

By

NEW YORK, June 3, 2026 /PRNewswire/ — Expert Consumers has recognized EZContacts as the top overall retailer for buying contact lenses online in 2026, citing the company’s mix of competitive pricing, broad brand selection, prescription-based ordering, and practical support for repeat vision purchases.

EZContacts is an online eyewear retailer offering contact lenses, prescription eyewear, designer sunglasses, readers, eye care products, and more. Its contact lens catalog includes major names such as Acuvue, Air Optix, Bausch + Lomb, Biofinity, Biotrue, CooperVision, DAILIES, FreshLook, MyDay, Proclear, PureVision, and other top brands.

Online contact lens retailers have become a primary purchasing channel for millions of wearers. The question for most shoppers is no longer whether to buy online. Rather, they want to know which retailer consistently delivers on price, accuracy, and convenience across multiple orders.

Why EZContacts Stands Out for Buying Contact Lenses Online

Contact lenses are not a category where shoppers browse casually. Most wearers already have a prescription from their eye doctor, often with a specific contact lens brand, prescription, and wear schedule. What they want from a retailer is simple: the right product, at a fair price, without unnecessary friction.

EZContacts carries an extensive catalog of major contact lens brands. Prescription handling is built into the process. Customers can submit a valid prescription, provide their eye care provider’s details for direct verification, or upload documentation after ordering. The same applies to color contact lenses, including plano, which require a valid prescription under federal law.

The site also carries eyeglasses, sunglasses, readers, and eye care products, rounding out its position as a full-service online vision retailer.

Competitive Pricing and the Case for EZ-Refill

Price remains one of the top reasons consumers compare retailers when buying contact lenses online. Since lenses are often purchased several times a year, even modest savings can matter over time.

EZContacts has built much of its appeal around competitive pricing on brand-name contact lenses and eyewear. Customers often point to value as a reason for choosing the retailer, particularly when comparing online pricing against traditional retail options.

The company also promotes a 105% price-match guarantee for eligible products. These features are especially relevant in a category where shoppers may already know the exact product they need and are simply looking for a better total cost.

Shipping and reordering features also support the value proposition. EZContacts offers free 5 to 7-business-day shipping on qualifying orders, according to company information.

EZContacts also has a loyalty program called EZPoints, earning customers one point for every two dollars spent on eligible items. Points activate 90 days after an order ships.

FSA, HSA, and Out-of-Network Insurance: What Shoppers Should Know

Many customers also need to manage FSA or HSA payment rules, insurance reimbursement, receipts, and prescription documentation.

EZContacts accepts FSA and HSA cards for eligible vision-related items, such as prescription glasses and contact lenses. Customers can enter these cards at checkout like a standard debit or credit card, subject to plan rules and product eligibility.

The retailer also supports customers with insurance plans that include out-of-network coverage. In those cases, EZContacts provides a form that shoppers can fill out to start the process, with reimbursement handled by the insurance company. This may help shoppers who want to buy online while still using available vision benefits.

The Best Place to Buy Contact Lenses Online

Expert Consumers’ recognition of EZContacts comes as more consumers look for online retailers that make it easier to order contact lenses while still following prescription requirements. The strongest retailers in this space are not just those with large catalogs or low prices. They are platforms that make recurring vision purchases easier without removing the safeguards that contact lenses require.

EZContacts stands out for consumers who already have a valid prescription and want a practical way to reorder brand-name contact lenses online. Its strengths include competitive pricing, broad brand availability, prescription submission options, support for FSA and HSA cards, out-of-network insurance claim assistance, rewards, and refill convenience.

For many repeat buyers, EZContacts offers a balanced online model. It brings together the practical details that matter most in contact lens shopping. It offers a range of products, a streamlined prescription process, competitive pricing, and support for repeat purchases.

The full review of EZContacts is available at Expert Consumers.

About EZContacts.com

EZContacts.com is an online retailer of prescription eyewear, designer sunglasses, and contact lenses, keeping the very best and most reputable products. Since 2005, EZContacts.com’s goal has been to continually add new features and services to ensure customer satisfaction. Affordable luxury and exceptional customer service are the hallmarks of EZContacts.com.

About ExpertConsumers.org: Expert Consumers delivers news and insights on consumer products and services. As an affiliate, Expert Consumers may earn commissions from sales generated using links provided.

View original content:https://www.prnewswire.com/news-releases/contact-lenses-online-2026-ezcontacts-recognized-as-top-overall-retailer-by-expert-consumers-302788919.html

SOURCE ExpertConsumers.org

Continue Reading

Trending